Orgenesis (ORGS) wins approval for 150M authorized shares and convertible deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Orgenesis Inc. reported that stockholders approved a major change to its capital structure at a special meeting on May 27, 2026. They authorized an increase in total common shares from 14,583,333 to 150,000,000, and the related charter amendment became effective when filed in Nevada on June 2, 2026.
Stockholders also approved a share issuance proposal tied to a Convertible Loan Agreement dated September 10, 2025 among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC, and ratified Kesselman & Kesselman C.P.A.s (a PwC member firm) as independent auditors for 2025. The filing reiterates that Orgenesis’ stock is no longer listed on Nasdaq and currently trades on the OTC Expert Market.
Positive
- None.
Negative
- None.
Insights
Large increase in authorized shares adds flexibility and dilution risk.
The approval to raise authorized common stock from 14,583,333 to 150,000,000 significantly expands Orgenesis’ capacity to issue new equity. This provides room for financings, conversions under existing agreements, or strategic transactions, but does not itself issue any new shares.
Stockholders also approved the share issuance proposal linked to the Convertible Loan Agreement with Theracell Laboratories IKE and Alpha Prosperity Fund SPC, aligning equity capacity with this financing structure. Ratification of Kesselman & Kesselman as 2025 auditors is routine. Future disclosures in periodic reports will be important for understanding how much of the new authorization is ultimately used.
8-K Event Classification
3 items: 5.03, 5.07, 9.01
3 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Authorized common stock before: 14,583,333 shares
Authorized common stock after: 150,000,000 shares
Special meeting quorum: 6,415,731 shares; 65.27%
+5 more
8 metrics
Authorized common stock before
14,583,333 shares
Authorized common stock prior to charter amendment
Authorized common stock after
150,000,000 shares
Authorized common stock after June 2, 2026 amendment
Special meeting quorum
6,415,731 shares; 65.27%
Shares represented and percentage of outstanding entitled to vote
Votes for share increase
5,153,345 for; 61,005 against; 1,201,381 abstain
Proposal 1 vote to increase authorized common stock
Votes for share issuance proposal
5,172,526 for; 27,026 against; 1,201,280 abstain
Proposal 2 Convertible Loan Agreement share issuance approval
Votes for auditor ratification
6,400,038 for; 14,552 against; 1,141 abstain
Proposal 3 ratifying Kesselman & Kesselman as 2025 auditors
Nasdaq Form 25 filing date
May 8, 2025
Date Nasdaq filed to delist Orgenesis common stock
Special meeting date
May 27, 2026
Date Orgenesis held the special stockholder meeting
Key Terms
Convertible Loan Agreement, OTCQX, Pink Limited, OTC Expert Market, +2 more
6 terms
Convertible Loan Agreement financial
"The approval of the Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC"
A convertible loan agreement is a contract where a lender provides cash to a company as a loan but with an option to swap the loan balance for company shares instead of being repaid in cash. For investors, it matters because conversion can change ownership percentages, affect future share value and dilution, and determine whether the lender is treated like a creditor or a shareholder — like lending someone money with a ticket that can later be exchanged for part-ownership.
OTCQX market
"The Company’s common stock began trading on the OTCQX operated by the OTC Markets Group, Inc."
OTCQX is the highest tier of the over‑the‑counter (OTC) marketplaces where shares of companies that aren’t listed on major stock exchanges trade. Think of it as a “premium shelf” for OTC stocks: companies must meet stricter financial and disclosure standards, which can mean clearer information, potentially better investor confidence and somewhat easier trading than lower OTC tiers. Investors watch OTCQX listings as a signal of relative transparency and credibility among OTC-traded firms.
Pink Limited market
"On June 3, 2025, OTC Markets moved the Company’s common stock from OTCQX to the Pink Limited tier."
Pink Limited is a classification for stocks traded on the over‑the‑counter market that have very limited public information and do not meet higher disclosure standards. It signals the company provides little or no regular financial reporting, making it hard to verify its business or performance. For investors this matters because limited transparency increases the chance of sudden price swings, illiquidity, and fraud risk — like buying a used car with no service history.
OTC Expert Market market
"On July 29, 2025, OTC Markets moved the Company’s common stock from Pink Limited to the OTC Expert Market tier."
An OTC expert market is an over-the-counter trading venue where securities that don’t meet the rules of main exchanges are bought and sold, and access is typically limited to professional or sophisticated investors. It matters to investors because these markets often have less public information, lower trading volume and higher price swings — like a specialized flea market where only experienced buyers trade rarer, riskier items, so potential reward and risk are both amplified.
independent registered public accounting firm financial
"the ratification of the appointment of Kesselman & Kesselman C.P.A.s ... as our independent registered public accounting firm for the fiscal year ending December 31, 2025"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Certificate of Amendment regulatory
"Certificate of Amendment to Articles of Incorporation of the Company, dated June 2, 2026."
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
FAQ
What capital change did Orgenesis (ORGS) stockholders approve at the May 27, 2026 special meeting?
Stockholders approved an amendment increasing authorized common stock from 14,583,333 to 150,000,000 shares. This change expands Orgenesis’ ability to issue equity in the future for financings, conversions, or other corporate purposes, though it does not immediately create or sell any new shares.
What is the Convertible Loan Agreement approved by Orgenesis (ORGS) stockholders?
Stockholders approved a Convertible Loan Agreement dated September 10, 2025 among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC. They also approved the potential issuance of Orgenesis common stock under this agreement, aligning shareholder consent with future share issuances from the convertible financing.
Which auditing firm did Orgenesis (ORGS) stockholders ratify for fiscal 2025?
Stockholders ratified Kesselman & Kesselman C.P.A.s, a member firm of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm for the year ending December 31, 2025. The ratification vote was strongly favorable, with 6,400,038 for, 14,552 against, and 1,141 abstentions.
Where does Orgenesis (ORGS) common stock currently trade and what happened to its Nasdaq listing?
Orgenesis’ common stock is quoted on the OTC Expert Market. Nasdaq filed Form 25 on May 8, 2025 to delist the shares, and deregistration under Section 12(b) occurred 90 days later. The stock previously moved from OTCQX to Pink Limited, then to the OTC Expert Market tier.